tbuckley/cabot-search huggingface dataset:
Family history of cancer and family history of smoking in lung cancer risk by histology
Authors: Ying Gao, Alisa Goldstein, Dario Consonni, Neil Caporaso, Lynn Goldin, Maria Landi
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

3127 

Lung cancer is the cancer with the highest mortality rate in the Western world. Tobacco smoking, and, to a lesser extent, genetic factors are associated with lung cancer risk. In particular, consistent association between family history of lung cancer and lung cancer risk has been reported, but no study has systematically examined the effect of family history of lung cancer and family history of smoking on lung cancer risk by histology. We quantified the risk of lung cancer among persons with family history of lung cancer and family history of smoking in the Environment And Genetics in Lung cancer Etiology (EAGLE) study, including 2101 cases and 2120 population-based controls recruited in Italy from 2002 to 2005. Family history of cancer and family history of smoking were collected through a computer-assisted personal interview questionnaire. Odds ratios (ORs) and 95% CI from logistic regressions were calculated to quantify the association between family history of cancer or smoking and lung cancer risk. Age, gender, residency, education, and personal cigarette smoking exposure were used for adjustment in the models. Family history of lung cancer in any family member was significantly associated with increased lung cancer risk (OR=1.52, 95% CI=1.22-1.90), and the lung cancer odds associated with father’s, mother’s and siblings’ history of lung cancer were 1.37 (95% CI=1.01-1.87), 2.21 (95% CI=1.11-4.41), and 1.50 (95% CI=1.09-2.06), respectively. Further adjustment for family history of smoking did not substantially modify the results. The association was stronger among non smokers (OR=1.88, 95% CI =1.09-3.24) and people with younger age (<55 year) (OR 2.95, 95% CI 1.43-6.08). Notably, family history of lung cancer was associated with increased risk of adenocarcinoma (OR=1.86, 95% CI=1.29-2.67) and squamous cell carcinoma (OR=1.71, 95% CI=1.29-2.27), but not with small cell carcinoma (OR=0.95, 95% CI=0.53-1.72). However, this latter group only included 19 cases. In contrast, family history of smoking was associated only with increased risk of small cell carcinomas (OR=3.81, 95% CI=1.06-13.7). This study confirms a heritability component in lung cancer risk. Moreover, it suggests that genetics and shared environment may play different roles in small cell vs. non small cell lung cancer risk.
5-Iodo-2-Pyrimidinone-2′-Deoxyribose (IPdR, NSC-726188) pharmacokinetic study in F344 rats
Authors: Jerry D. Johnson, Seongwon Hong, Natalie South, Brian Burback, Patricia Tosca, John Merrill, Irma Grossi, Timothy Kinsella, Jim O. Peggins
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

579 

The purpose of this study was to generate non-clinical PK information for IPdR, a pro-drug for the radiosensitizer 5-iodo-2′-deoxyuridine (IUdR). Male and female (M/F) F344 rats (10/sex/group), 9 to 11 weeks of age, were administered IPdR (NSC-726188) p.o. for 28 days at dosages of 1200 mg/m2/day (0.2 g/kg/day) or 6000 mg/m2/day (1.0 g/kg/day). The dosing volume was 10 mL/kg. Serial blood samples were collected at specified time points after dosing on Days 1 and 28 (two samples/time point/sex/dosage group) and the plasma analyzed for IPdR and IUdR using a validated liquid chromatography with mass spectrometry detection (LC-MS) method over a concentration range of 0.05 to 2 μg/mL (0.148 to 5.92 μM for IPdR, and 0.141 to 5.65 μM for IUdR). A one-compartment model with no lag phase and first order absorption and elimination were used to obtain a best fit curve for IPdR and noncompartmental analysis (NCA) was used to obtain a best fit curve for IUdR. For IPdR, absorption rate constant and half-life, Tmax, and apparent clearance (CL_F) parameters were similar for all dosage groups and sexes, following single and repeated administrations with overall mean (± sd) values of 0.0306 ± 0.018 min-1, 29.5 ± 16.0 min, 86.3 ± 27.8 min, and 0.705 L/min/m2, respectively. Predicted Cmax, apparent volume of distribution (V_F), and elimination half-lives were also similar for M/F following single and repeated administrations with overall mean (± sd) values of 21.9 ± 3.7 μM, 100 L/m2, and 124.0 ± 14.0 min for the 1200 mg/m2 group and 50.5 ± 4.9 μM, 300 L/m2, and 294.2 ± 137.9 min for the 6000 mg/m2 group, respectively. While AUC values were generally proportional to dosage, Day 1 AUCs were greater than Day 28 AUCs for a given dosage group. For IUdR, observed Cmax values were similar across all groups with overall mean (± sd) values of 3.12 ± 0.79 μM on Day 1 and 1.37 ± 0.52 μM on Day 28. Tmax generally occurred within 15 min of dosing. IUdR elimination half-lives on Day 1 were 3.4, 5.7, 5.0, and 8.3 hours and on Day 28 were 9.4, 6.7, 4.4, and 27.1 hours for the male and female 1200 and 6000 mg/m2 dosage groups, respectively. The IUdR Day 1 AUC values were similar for both males and females in a given dosage group. Variability precluded reliable interpretation of Day 28 IUdR AUC values. In summary, there were no sex-dependent effects observed, the absorption and elimination kinetics were first-order over the dose range studied, and repeated administration appeared to enhance elimination of IPdR, based on the decrease in AUC from Day 1 to Day 28. [Supported by NCI contract N01-CM-42200.] Page # of 1
Granzymes: Major Players in Vascular Remodelling, Atherosclerosis and Longevity
Authors: David J Granville
Journal: Circulation (2007)

Abstract 285 Rani P Cruz, Wendy A Boivin, Ciara M Chamberlain, Jonathan C Choy, Bruce M McManus, David J Granville, University of British Columbia, Vancouver, BC, Canada David J Granville, 2007 Finalist and Presenting Author
Community Medicine in Developing Countries.
Authors: Abdel red Omrab
Journal: Annals of Internal Medicine (1976)

At long last!" may well be the first reaction of most interested persons encountering this book; the need for such a text for health workers, educators, and students of community medicine in developing countries has indeed been pressing.Its publication is particularly timely because there is growing aware- ness of the importance of an interdisciplinary approach to health care delivery that is relevant and acceptable for each local setting, replacing the traditional approach of categorical health projects or technology-intensive, transplanted Western medicine.
Cell adhesion pathways in mouse retinoblastoma
Authors: Adithi Mohan, Nikia Laurie, Michael Dyer
Journal: Clinical Cancer Research (2007)

B66   It is well established that the initiating genetic lesion for retinoblastoma is inactivation of the RB1 gene presumably in proliferating retinal progenitor cells in utero. Recent studies have indicated that the second genetic lesion is suppression of the p53 pathway by MDMX amplification. We have generated a mouse model of retinoblastoma from Rb+/-;p107-/-;p53-/- retinal progenitor cells. Clonal lines were derived from this tumor that was of 2 distinct morphologies - one that grew as aggregates in suspension and the other that grew attatched to the substrate. To further characterize changes in the retinoblastoma cells, microarray analysis of each of the clones and primary tumors were performed. Some of the genes that showed 2-fold changes were Alpha-Catenin, Cdh11, Egf, Egfr, Itga4, Itgav, Itgb6, MMP9, PDGFD, RhoB, Stat5a and Stat5b and we are in the process of confirming these expression levels by Real-Time PCR. Immunostaining and western blotting also show differences in levels and localization of some of these genes among the adherent and non-adherent clones. We predict that these differences could be associated with differences in morphologies and adhesiveness among the adherent and non-adherent clones.
Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C
Authors: Akinori Kasahara, Norio Hayashi, Kiyoshi Mochizuki, Masahide Oshita, Kazuhiro Katayama, Michio Kato, Manabu Masuzawa, Harumasa Yoshihara, Masafumi Naito, Takeshi Miyamoto, Atsuo Inoue, Akira Asai, Taizou Hijioka, Hideyuki Fusamoto, Takenobu Kamada
Journal: Journal of Hepatology (1997)
Gene expression signature of invasive primary breast cancer cells is transient in nature
Authors: Sumanta Goswami, Jeffrey B. Wyckoff, Weigang Wang, Glicella M. Salazar-Desimone, John S. Condeelis
Journal: Cancer Research (2006)

1843   Gene expression profiling with microarrays has shown promise in prognosis by identifying patterns of expression that are correlated with metastasis. However, these patterns of expression do not reveal clues as to mechanisms of invasion and metastasis and can appear as random sets of genes with unrelated functions. The process of progression of the tumors from early carcinoma to metastatic carcinoma has been compared to Darwinian evolution in which favorable mutations are accumulated in the cells during tumor progression. A solution to this paradox may be to consider expression profiling of invasive carcinoma cells, which are caught in the act of invading inside tumors, reveal gene expression patterns that are grouped into pathways of functionality and give insight into mechanism. The patterns of gene expression of invasive cells are usually not seen in their entirety in expression profiles derived from whole tumors suggesting that invasion, and the patterns of gene expression that support it, are transitory. This leads to a new model of invasion called the tumor microenvironment invasion model (TMIM) where tumor progression leads to the development of microenvironments encoded within the tumor which elicit the transient gene expression patterns that support invasion. TMIM is a very different view of the events leading to metastasis compared to the conventional model. TMIM is consistent with the finding that genes encoding the tumor microenvironment for invasion and metastasis can be encoded throughout the bulk of the tumor and that they may not be related as pathways of functionality. TMIM is also consistent with the collection of invasive tumor cells using the  in vivo  invasion assay where any part of metastatic, but not non metastatic tumors, are capable of supplying cells in response to chemotactic ligands. An experimental plan was designed to understand the importance of microenvironment in the regulation of the expression of genes that regulate motility of the cells. The invasive tumor cells were collected by chemotaxis and removed from the microenvironment. Further, the cells which have successfully intravasated into the blood and those that have formed successful lung mets were collected from blood and the lungs by FCAS sorting. The resident tumor cells were used as controls for the experiment. It was observed that the gene expression took three different patterns. Some of the genes were stably over expressed in the invasive, intravasted and mets, indicating a stable genetic change in these cells. On the other hand majority of the other genes indicated in the invasive gene expression signature returned to the levels of non-invasive cells in the mets. We are currently studying the molecular mechanism of these stable and transient changes in the gene expression pattern of the invasive cells.
糖化血红蛋白A1c浓度与心血管疾病及全因死亡率增加相关——糖化血红蛋白A1c浓度与冠心病事件、心血管事件、全因死亡率之间的相关性如何？
Authors: Khaw, Wareham, Bingham, Ronald, Sigal（点评）, 刘冰（译）
Journal: BMJ (2005)
The behavior therapies: therapeutic breakthrough or latest fad?
Authors: A K Shapiro
Journal: American Journal of Psychiatry (1976)

The author critically examines the evidence for the effectiveness of the behavior therapies as described in the American Psychaitric Association's task force report on behavior therapy. He concludes that current attempts to evaluate behavior therapy suffer from inadequate methodology and that the claims for its therapeutic efficacy are excessive and unsupported by the controlled clinical evidence.
Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results
Authors: Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A. Fridrik, Josef Thaler, Alois Lang, Richard Greil
Journal: Blood (2013)
New Threats and Old Enemies
Authors: Janet M Torpy
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sulindac induces the expression of the carcinogen metabolizing enyzme cytochrome P450 1A1 in vitro and in vivo
Authors: Henry P. Ciolino, Omar Memon, Chistopher J. MacDonald, Grace C. Yeh
Journal: Cancer Research (2004)

1379   Sulindac, a widely used non-steroidal anti-inflammatory drug, has been shown to inhibit aryl hydrocarbon (AH)-induced carcinogenesis. In the present study we have examined the effect of sulindac on the activity and expression of the enzymes that mediate the initial steps of AH detoxification, the cytochromes p450 (CYP) 1A1, 1A2, and 1B1. In the HepG2 human liver cancer cell line, sulindac caused a dose-dependent, sustained increase in CYP enzyme activity. Sulindac treatment resulted in a profound, dose-dependent increase in the mRNA of CYP1A1 and lesser increases in CYP1A2 and CYP1B1 mRNA. The increase in CYP1A1 mRNA induced by sulindac was, like enzyme activity, sustained for several days after the initial treatment. Sulindac induced transcription of the CYP1A1 gene, as measured by the level of heterogeneous nuclear CYP1A1 RNA, and by the ability of the transcription inhibitor actinomycin D to block sulindac-induced CYP1A1 mRNA. Sulindac treatment of rats resulted in a dose-dependent increase in hepatic CYP enzyme activity and in the expression of CYP1A1 and CYP1B1 mRNA, demonstrating that sulindac is also active in vivo. These results demonstrate that sulindac modulates the expression and activity of CYP enzymes both in vitro and in vivo, and provide a novel mechanism to explain the established chemopreventive activity of sulindac.
Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression
Authors: M E Thase, A G Mallinger, D McKnight, J M Himmelhoch
Journal: American Journal of Psychiatry (1992)

Few trials of monoamine oxidase inhibitors (MAOIs) in tricyclic-resistant depression have had double-blind conditions. In the authors' previous double-blind comparison of tranylcypromine and imipramine in anergic bipolar depression, tranylcypromine was significantly more effective. This investigation was a crossover study of nonresponders in the initial study.The subjects were 16 outpatients with anergic bipolar depression. Fourteen had not responded to 4 weeks of treatment with at least 30 mg/day of tranylcypromine or 150 mg/day of imipramine, and two patients were crossed over because of intolerable side effects from the initial drug. The crossover medication was prescribed as in the initial double-blind study.Twelve patients were crossed over from imipramine to tranylcypromine; nine of them responded to tranylcypromine. Highly significant improvements were documented on the Hamilton, Beck, and Pittsburgh Reversed Vegetative Symptom Scales. Four patients were switched from tranylcypromine to imipramine, but only one responded.The high rates of response to tranylcypromine in both the initial and crossover double-blind studies document the efficacy of MAOI treatment for anergic bipolar depression. Moreover, the results further illustrate the utility of MAOIs in tricyclic-resistant depressions.
Noninfluenza Vaccination Coverage Among Adults—United States, 2011
Authors: Walter W Williams, Peng-Jun Lu, Alissa O'Halloran, Carolyn B Bridges, Tamara Pilishvili, Craig M Hales, Lauri E Markowitz
Journal: JAMA (2013)

Vaccinations are recommended throughout life to prevent vaccine-preventable diseases and their sequelae. Adult vaccination coverage, however, remains low for most routinely recommended vaccines and well below Healthy People 2020 targets. In October 2013, the Advisory Committee on Immunization Practices (ACIP) approved the adult immunization schedule for 2014. With the exception of influenza vaccination, which is recommended for all adults each year, vaccinations recommended for adults target different populations based on age, health conditions, behavioral risk factors (e.g., injection drug use), occupation, travel, and other indications. To assess vaccination coverage among adults aged ≥19 years for selected vaccines, CDC analyzed data from the 2012 National Health Interview Survey (NHIS). This report summarizes the results of that analysis for pneumococcal, tetanus toxoid-containing (tetanus and diphtheria vaccine [Td] or tetanus and diphtheria with acellular pertussis vaccine [Tdap]), hepatitis A, hepatitis B, herpes zoster (shingles), and human papillomavirus (HPV) vaccines by selected characteristics (age, race/ethnicity, and vaccination target criteria). Influenza vaccination coverage estimates for the 2012-13 influenza season have been published separately. Compared with 2011, only modest increases occurred in Tdap vaccination among adults aged 19-64 years, herpes zoster vaccination among adults aged ≥60 years, and HPV vaccination among women aged 19-26 years; coverage among adults in the United States for the other vaccines did not improve. Racial/ethnic gaps in coverage persisted for all six vaccines and widened for Tdap, herpes zoster, and HPV vaccination. Increases in vaccination coverage are needed to reduce the occurrence of vaccine-preventable diseases among adults. The Community Preventive Services Task Force and other authorities have recommended that health-care providers incorporate vaccination needs assessment, recommendation, and offer of vaccination into routine clinical practice for adult patients.
Abstract 10293: Exosome-mediated Transfer of Pro-angiogenic miRNAs From Mesenchymal Progenitor Cells to Endothelial Cells: An Important Mechanism for Promoting Angiogenesis
Authors: Min Gong, Bin Yu, Jingcai Wang, Yigang Wang, Ronald W Millard, Muhammad Ashraf, Meifeng Xu
Journal: Circulation (2013)

Background: Previously, we demonstrated that concentrated conditioned medium (CdM) of mesenchymal stem cells promoted angiogenesis of human umbilical vein endothelial cells (HUVEC). Angiogenic miRN...
Abstract 1438: Myocardial Infarction Associated SNPs on Chromosome 9p21.3 are Associated with Coronary Artery Calcification but Not Carotid Intimal Medial Thickness in the Amish
Authors: Kiran Musunuru, Alan R Shuldiner, Haiqing Shen, Elizabeth Clearfield, Kathleen A Ryan, Jeffrey R O'Connell, Lawrence F Bielak, Patricia A Peyser, Braxton D Mitchell, Wendy Post
Journal: Circulation (2008)
Development of a Risk Score for Incident Atrial Fibrillation in the Community: the Framingham Heart Study
Authors: Renate Schnabel
Journal: Circulation (2008)

Abstract 1254   Renate B Schnabel, NHLBI’s Framingham Heart Study, Boston, MA; Lisa M Sullivan, Boston Univ Sch of Public Health Dept of Biostatistics, Boston, MA; Daniel Levy, Ctr for Population Studies, Natl Heart, Lung, and Blood Inst, Bethesda, MD; Michael J Pencina, NHLBI’s Framingham Heart Study, Boston, MA; Joseph M Massaro, Mathematics and Statistics Dept, Boston Univ, Boston, MA; Ralph B D’Agostino Sr, Boston Univ Sch of Public Health Dept of Biostatistics, Boston, MA; Christopher Newton-Cheh, Broad Inst of Harvard and Massachusetts Inst of Technology, Cambridge, MA; Jared W Magnani, Cardiology Dept, Boston Univ, Boston, MA; Thomas M Tadros, William B Kannel, Thomas J Wang, NHLBI’s Framingham Heart Study, Boston, MA; Patrick T Ellinor, Cardiovascular Res Ctr and Cardiac Arrhythmia Service, Massachusetts General Hosp, Boston, MA; Philip A Wolf, Ramachandran S Vasan, Emelia J Benjamin, NHLBI’s Framingham Heart Study, Boston, MA
Bone Marrow Core Biopsy Adequacy and Variability in the United Stated and Canada: A Multicenter Retrospective Study
Authors: Mihai Merzianu, Richard Cheney, Adrienne Groman, George Deeb, Gregory Wilding, Claudiu Cotta, Ramila Amre, Manjula Balasubramanian, Guilherme Brandao, Russell K. Brynes, Sindhu Cherian, Elizabeth Courville, David Czuchlewski, Guang Fan, David Grier, Daniela Hoehn, Robert E Hutchison, Kedar V. Inamdar, Ridas Juskevicius, Prabhjot Kaur, John Lazarchick, Michael R Lewis, Rodney R. Miles, Jerome B. Myers, Michel Nasr, Hina Naushad, Horatiu Olteanu, Attilio Orazi, Vishnu VB Reddy, Valentin G Robu, Gratian Salaru, Julie Teruya-Feldstein, Neerja Vajpayee, Jeffrey Vos, Ling Zhang, Shanxing Zhang, Ashley V Sedelmeyer, Vivian Arguello, Le Aye, Sharon Barouk, Elisa F Brega, Richie Carpenter, James E. Coad, Alana DiPonio, Fernandez Garcia, John Grantham, Sinisa Ivelja, Robert McKenna, Kieran Sultan, Matthew B Thomsen, Jie Xu, LoAnn Peterson, Vishala T. Neppalli
Journal: Blood (2014)
Relation of C pneumoniae antibodies to ischaemic heart disease
Authors: D. Taylor-Robinson, B. J Thomas, L. von Hertzen, R. Isoaho, S.-L. Kivela, P. Saikku
Journal: BMJ (1999)

Cancer survival in Britain Cancer chemotherapy costs moneyEditor-I strongly endorse Sikora's claim that poor rates of survival from cancer in the United Kingdom reflect a lack of NHS resources. 1Increasing the number of specialist oncologists will not, however, make up for the massive shortfall in funds required to provide these oncologists with the essential tools of their trade.Recent review of the budgetary allocation to Addenbrooke's Oncology Centre identified that, on average, £1700 a year is available to spend on drugs for any individual patient with cancer.Since a single course of chemotherapy may cost between £50 and £1500, oncologists cannot be expected to deliver the quality of care the public expects to receive.There are no other untapped sources of funding.Our clinical practice is already heavily subsidised: about one in six of all new patients with cancer referred to Addenbrooke's receives his or her standard chemotherapy courtesy of funds raised from industry sponsored research.The government cannot claim commitment to improving cancer care while patients are being denied effective treatments on the grounds of lack of affordability.